On Demand: Navigating New Terrain in Chemotherapy-induced Anemia: Hem/Onc Perspectives and Evidence-supported Strategies for Improving Care with Intravenous Iron
This timely educational activity is targeted to hematologists/oncologists and their interprofessional team of hematology/oncology nurses, nurse practitioners, physician assistants, and pharmacists who manage patients with cancer. After providing comprehensive context for cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states, including etiology, pathophysiology, clinical gravity, and the central role of inflammation, top hem/onc experts will guide attendees through an incisive overview of the evolving and expanding clinical trial evidentiary base for IV iron products for CRA/CIA management, emphasizing both combinatorial and monotherapeutic approaches. Recent pivotal monotherapy trials such as IRON-CLAD will be a preeminent focus. An exploration of current expert consensus guidelines from NCCN, ASCO/ASH, and ESMO will segue the session into a case-based conclusion that will allow attendees to implement all they have learned into real-world clinical scenarios.
Hematologists/oncologists and their interprofessional team of hematology/oncology nurses, nurse practitioners, physician assistants, and pharmacists who manage patients with cancer.
- Review the basic facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with analysis of how these distinctions impact iron repletion strategies in the oncology treatment setting.
- Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy induced anemia (CIA), with an emphasis on the role of inflammation and elevated hepcidin levels.
- Evaluate the clinical gravity of CRA and CIA, in terms of both morbidity/mortality and patient-reported quality-of-life metrics.
- Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for CRA/CIA, and identify how the innovative nanoparticle design of next-generation IV iron agents dramatically improves product safety profiles, with anaphylaxis rates as low as 0.1%.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for CRA/CIA evaluating IV iron in combinatorial regimens (i.e., IV iron + ESA) and as monotherapy (i.e., IRON-CLAD, etc.).
- Explore what it means to circumvent “functional iron block” using IV iron therapies.
- Discuss current expert consensus CRA/CIA management guidelines (NCCN, ASCO/ASH, ESMO).
- Use a real-world patient case-based format to interpolate the expanding IV iron evidentiary base regarding the impact of inflammation and hepcidin on iron availability and utilization, especially in a hyperinflammatory state like cancer, and apply guideline-endorsed principles into practice.
- Compare and contrast FDA-approved IV iron products, including new indications and dosing regimens.
- Design innovative, evidence-supported clinical tools that can interface with institutional EHRs, such as diagnostic algorithms, digitalized checklists to promote CRA/CIA GDMT, and Ganzoni’s formula to determine iron repletion dosages.
Friday Satellite Symposium on Navigating New Terrain in Chemotherapy-induced Anemia: Hem/Onc Perspectives and Evidence-supported Strategies for Improving Care with Intravenous Iron preceding the 64th ASH Annual Meeting and Exposition.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
10 min Welcome and Introductions/Pre-test
40 min The Role of Iron Deficiency in Cancer-related Anemia: Etiology, Pathophysiology, and Foundational Treatment Principles
55 min Infusing Renewed Hope into Cancer Care: The Evolving Evidentiary Base and Guideline Updates for IV Iron Products
60 min Hem/Onc Expert Roundtable: Exploring the Clinical and Budgetary Implications of Using IV Iron Therapies in Cancer Care
15 min Conversations with the Experts/Audience Q&A/Post-test
George M. Rodgers, MD, PhD (Activity Chair)
Professor of Medicine
Division of Hematology and Hematologic Malignancies
University of Utah School of Medicine and Huntsman Cancer Center
Salt Lake City, UT
Michael Auerbach, MD, FACP
Clinical Professor of Medicine
Georgetown University School of Medicine
Patricia Ford, MD
Clinical Professor of Medicine, Hematology/Oncology
University of Pennsylvania, Penn Medicine
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
George M. Rodgers, MD, PhD–has disclosed that he is an advisor or consultant to Pharmacosmos.
Michael Auerbach, MD–has disclosed that he receives research support in the form of data management from COVIS Pharma.
Patricia Ford, MD–has disclosed that she is an advisor or consultant to Cardinal Health and Kite.
Jillian L. McInerney, CRNP, MSN–has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 3.0 contact hours.
Upon completion of a CE request form, statements of credit for physicians and nurses will be issued within 30 business days.
- 3.00 AMA PRA Category 1 Credit™
- 3.00 ANCC
- 3.00 Participation